Search results
What Is Psoriatic Arthritis? 3 MDs Weigh In
PopSugar· 5 days agoPsoriasis affects about three percent of American adults, but the disorder can raise the risk of having more than skin scales and plaques. About 30 percent of people with psoriasis will develop ...
Amjevita and dosage: Strengths, forms, how to inject, and more
Medical News Today· 3 days agoAmjevita comes as a solution subcutaneous injection. Your doctor will determine the best dosage to...
Janssen-Cilag seeks expanded EMA approval for TREMFYA
Pharmaceutical Technology via Yahoo Finance· 5 days agoGuselkumab has been approved in the EU to treat moderate to severe plaque psoriasis in adults who...
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Medscape· 5 days agoUnlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.
Psoriasis pain: Prevalence and how to manage it
Medical News Today· 5 days agoPeople may describe psoriasis pain as itchy, achy, or stinging, with the feeling varying from person to person. Strategies such as using distraction,...
Amgen (NASDAQ:AMGN) Price Target Cut to $328.00
ETF DAILY NEWS· 2 days agoAmgen (NASDAQ:AMGN – Get Free Report) had its price target reduced by Royal Bank of Canada from $332.00 to $328.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently ...
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
Zacks via Yahoo Finance· 3 days agoTremfya is presently approved to treat certain patients with plaque psoriasis and active psoriatic ...
AbbVie (NYSE:ABBV) Price Target Cut to $180.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 7 days agoAbbVie (NYSE:ABBV – Free Report) had its price objective cut by BMO Capital Markets from $195.00 to $180.00 in a report published on Monday morning, Benzinga reports. A number of other analysts ...
AbbVie (NYSE:ABBV) Shares Down 0.5% After Analyst Downgrade
ETF DAILY NEWS· 6 days agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shares fell 0.5% on Monday after Barclays lowered their price target on the stock from $195.00 to $187.00. AbbVie traded as low as $158.56 and last ...
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 5 days agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports. Barclays‘s ...
